BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34584128)

  • 41. Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.
    Marnitz S; Tsunoda AT; Martus P; Vieira M; Affonso Junior RJ; Nunes J; Budach V; Hertel H; Mustea A; Sehouli J; Scharf JP; Ulrich U; Ebert A; Piwonski I; Kohler C
    Int J Gynecol Cancer; 2020 Dec; 30(12):1855-1861. PubMed ID: 33293284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer.
    Cuschieri K; Brewster DH; Graham C; Nicoll S; Williams AR; Murray GI; Millan D; Johannessen I; Hardie A; Cubie HA
    Int J Cancer; 2014 Dec; 135(11):2721-6. PubMed ID: 24740764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
    Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
    J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer.
    Jonska-Gmyrek J; Gmyrek L; Zolciak-Siwinska A; Kowalska M; Kotowicz B
    Curr Med Res Opin; 2019 Apr; 35(4):595-601. PubMed ID: 30019594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy.
    Lin G; Yang LY; Lin YC; Huang YT; Liu FY; Wang CC; Lu HY; Chiang HJ; Chen YR; Wu RC; Ng KK; Hong JH; Yen TC; Lai CH
    Eur Radiol; 2019 Feb; 29(2):556-565. PubMed ID: 30051142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and prognostic factors of concurrent chemoradiotherapy in patients with stage Ib3 and IIa2 cervical cancer.
    Liu T; Kong W; Liu Y; Song D
    Ginekol Pol; 2020; 91(2):57-61. PubMed ID: 32141049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
    Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
    Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of p53 codon 72 polymorphism on the survival outcome in advanced stage cervical cancer patients in India.
    Bansal A; Das P; Kannan S; Mahantshetty U; Mulherkar R
    Indian J Med Res; 2016 Sep; 144(3):359-365. PubMed ID: 28139534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Cho O; Chun M; Chang SJ; Oh YT; Noh OK
    Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic implication of human papillomavirus types and species in cervical cancer patients undergoing primary treatment.
    Lau YM; Cheung TH; Yeo W; Mo F; Yu MY; Lee KM; Ho WC; Yeung AC; Law PT; Chan PK
    PLoS One; 2015; 10(4):e0122557. PubMed ID: 25855986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy.
    Wang CC; Lai CH; Huang HJ; Chao A; Chang CJ; Chang TC; Chou HH; Hong JH
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1111-20. PubMed ID: 20231068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes of concurrent chemoradiotherapy with weekly carboplatin in locally-advanced carcinoma of the uterine cervix patients.
    Sangkittipaiboon S
    J Med Assoc Thai; 2014 Jan; 97(1):12-9. PubMed ID: 24701724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
    Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
    J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 58. Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.
    Kim SW; Chun M; Ryu HS; Chang SJ; Kong TW; Lee EJ; Lee YH; Oh YT
    Strahlenther Onkol; 2017 Jul; 193(7):534-542. PubMed ID: 28357468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study.
    Chopra S; Deodhar K; Pai V; Pant S; Rathod N; Goda JS; Sudhalkar N; Pandey P; Waghmare S; Engineer R; Mahantshetty U; Ghosh J; Gupta S; Shrivastava S
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):161-168. PubMed ID: 30213750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.